Comparative Analysis of Metformin and Imeglimin: Exploring Therapeutic Implications

Authors:
Open Access
Publisher website
Google Scholar
Abstract
The landscape of type 2 diabetes mellitus (T2DM) management is evolving with the emergence of imeglimin alongside the longstanding use of metformin. While both drugs share structural similarities and target mitochondrial complex I, they exhibit distinct mechanisms of action and therapeutic effects. Imeglimin, with its mitochondrial modulation and competitive inhibition of complex I, holds promise in mitigating beta-cell dysfunction, improving insulin sensitivity, and offering potential cardiovascular benefits. Efficacy studies suggest comparable outcomes with metformin, underscoring the utility of imeglimin as a valuable addition to the T2DM armamentarium. There is mixed evidence on the cardio-renal benefits of metformin while imeglimin’s tissue-protective effects in preclinical studies offer a glimpse into potential cardiovascular advantages. Studies suggest imeglimin’s superior gastrointestinal tolerability. Imeglimin’s potential as an anti-diabetic agent is further underscored by its diverse combination options. In clinical practice, metformin remains a cornerstone in the management of T2DM. Imeglimin, with its lesser gastrointestinal side effects and theoretically lower risk of lactic acidosis, offers a compelling alternative, particularly in patients intolerant to metformin. With preliminary signs pointing toward potential cardiovascular and renal benefits of imeglimin, exploring its application in patients with atherosclerotic cardiovascular disease presents an enticing prospect. As the field advances, adopting a nuanced and personalized approach to T2DM management could lead to imeglimin carving out a significant niche in the dynamic landscape of diabetes therapeutics.

This publication has 33 references indexed in Scilit: